Racura Oncology Ltd
Racura Oncology Ltd operates as a Phase 3 clinical biopharmaceutical company for cancer care. Its lead asset is RCDS1 (E,E-bisantrene), a small molecule anticancer agent that primarily functions through G4-DNA & RNA binding to potent inhibition of the cancer growth regulator MYC. The company is advancing a proprietary formulation of RCDS1 (RC220) to address the unmet needs of patients across vari… Read more
Market Cap & Net Worth: Racura Oncology Ltd (FN3)
Racura Oncology Ltd (F:FN3) has a market capitalization of $13.37K (€13.03K) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #44643 globally and #7329 in its home market, demonstrating a -5.76% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Racura Oncology Ltd's stock price €1.31 by its total outstanding shares 9946 (9.95K).
Racura Oncology Ltd Market Cap History: 2026 to 2026
Racura Oncology Ltd's market capitalization history from 2026 to 2026. Data shows growth from $13.37K to $13.37K (0.00% CAGR).
Racura Oncology Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Racura Oncology Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of FN3 by Market Capitalization
Companies near Racura Oncology Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Racura Oncology Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Racura Oncology Ltd Historical Marketcap From 2026 to 2026
Between 2026 and today, Racura Oncology Ltd's market cap moved from $13.37K to $ 13.37K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €13.37K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Racura Oncology Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.37K USD |
| MoneyControl | $13.37K USD |
| MarketWatch | $13.37K USD |
| marketcap.company | $13.37K USD |
| Reuters | $13.37K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.